Accumulating evidence suggests that myeloid-derived suppressor cells (MDSCs) underpin an immunological checkpoint that is activated during inflammation or "inflammatory-like" conditions like cancer. Here, we discuss the identification of MDSCs in patients receiving allogeneic hematopoietic stem cell transplantation and their potential as therapeutic targets or tools for improving the efficacy o...

The goal of achieving measurable response with cancer immunotherapy requires counteracting the immunosuppressive characteristics of tumors. One of the mechanisms that tumors utilize to escape immunosurveillance is the activation of myeloid derived suppressor cells (MDSCs). Upon activation by tumor-derived signals, MDSCs inhibit the ability of the host to mount an anti-tumor immune response via ...

Myeloid cells developed evolutionarily as a major mechanism to protect the host. They evolved as a critical barrier against infections and are important contributors to tissue remodeling. However, in cancer, myeloid cells are largely converted to serve a new master-tumor cells. This process is epitomized by myeloid-derived suppressor cells (MDSC). These cells are closely related to neutrophils ...